Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models

2008219 citationsJournal Article

Authors

Good health and well-being

Published in: Journal of Pharmacology and Experimental Therapeutics

Volume 327, Issue 1, pp. 268-276

Field-Weighted Citation Impact: 9.32